新型异色胺四环类化合物作为5-HT2A激动剂用于治疗脑部疾病。
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.
Abstract
Provided herein are novel isotryptamine tetracycles as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating brain disorders, and processes for preparing such compounds.
摘要
本文提供了作为5-HT2A激动剂的新型异色胺四环化合物、药物组合物、此类化合物在治疗脑部疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain Disorders.新型异色胺四环类化合物作为5-HT2A激动剂用于治疗脑部疾病。
ACS Med Chem Lett. 2025 May 9;16(6):933-934. doi: 10.1021/acsmedchemlett.5c00246. eCollection 2025 Jun 12.
2
Novel Desamide Isotryptamine Tetracycles as 5‑HT2C Agonists for Treating Brain Disorders.新型去酰胺异色胺四环类化合物作为治疗脑部疾病的5-HT2C激动剂
ACS Med Chem Lett. 2025 May 21;16(6):976-977. doi: 10.1021/acsmedchemlett.5c00286. eCollection 2025 Jun 12.
3
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型苯基烷基胺作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 14;16(6):948-949. doi: 10.1021/acsmedchemlett.5c00269. eCollection 2025 Jun 12.
4
Novel Ergolines as 5‑HT2A Agonists for Treating Mood Disorders.新型麦角灵类化合物作为5-羟色胺2A受体激动剂用于治疗情绪障碍
ACS Med Chem Lett. 2025 May 21;16(6):974-975. doi: 10.1021/acsmedchemlett.5c00288. eCollection 2025 Jun 12.
5
Novel Pyridine Derivatives as 5‑HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 May 13;16(6):929-930. doi: 10.1021/acsmedchemlett.5c00244. eCollection 2025 Jun 12.
6
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
7
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
8
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
9
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
10
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.作为用于治疗精神疾病的5-HT2A激动剂的新型吡咯并吡啶化合物。
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
本文引用的文献
1
5-HT receptors: Pharmacology and functional selectivity.5-羟色胺受体：药理学与功能选择性
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.N，N-二甲基色胺的演变：从代谢途径到脑连接性
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Exploring DMT: Endogenous role and therapeutic potential.探索二甲基色胺：内源性作用及治疗潜力。
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
4
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
5
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.前扣带回皮层中5HT2A受体激活的抗抑郁和抗焦虑作用及其潜在理论机制——现有文献的综述
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
6
Psychedelic therapy in depression and substance use disorders.致幻剂治疗抑郁症和物质使用障碍。
Eur J Neurosci. 2024 Jul;60(2):4063-4077. doi: 10.1111/ejn.16421. Epub 2024 May 21.
Zotero 插件